A Translational Study of ATH-1017 in Mild to Moderate Alzheimer's Disease
Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate treatment effects of ATH-1017 in mild to moderate
Alzheimer's subjects with a randomized treatment duration of 26-weeks.